Company intelligence / Profile preview

States

Amsterdam, Netherlands

Ownership: Private
Development stage: Other

Overview

States Bio is a biotechnology company focused on developing transformative therapies for cardiovascular and metabolic diseases. The company's lead research efforts center on targeting Angiopoietin-like protein 3 (ANGPTL3) to treat lipid disorders such as dyslipidemia and hypertriglyceridemia. By leveraging monoclonal antibody technology, States Bio aims to provide potent and durable solutions for patients with high cardiovascular risk who are underserved by current standard-of-care treatments. The company operates primarily in the pre-clinical stage, advancing its pipeline toward regulatory filings.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Beyond the preview

Go deeper on States.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on States.

Explore the full profile